Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose provides caloric support, and sodium chloride corrects sodium and chloride deficits.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: 5 mEq potassium chloride in 100 mL D5 1/4 NS (0.225% NaCl) administered at a rate not exceeding 10 mEq/hour. Typical dose ranges from 10-40 mEq/day, depending on serum potassium level and clinical need.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Potassium itself has a distribution half-life of ~1 hour and an elimination half-life of ~12 hours in healthy individuals; clinical effect depends on intracellular shift and renal function.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% excreted unchanged. A small fraction is lost in sweat and feces (<5%).
Category C
Category A/B
Electrolyte
Electrolyte